Squamous cell carcinoma of the uterine cervix, Stage IIB (>
Conditions
Interventions
None listed
Sponsors
National Institutes for Quantum and Radiological Sciences and Technology
Forum for Nuclear Cooperation in Asia International Medical Center Saitama Medical University, Saitama, Japan Gunma University Hospital, Gunma, Japan Jichi Medical University Hospital, Tochigi, Japan Tokyo Womens Medical University Hospital, Tokyo, Japan Delta Limited Hospital, Dhaka, Bangladesh United Hospital Limited, Dhaka, Bangladesh The First Affiliated Hospital of Soochow University, Soochow, China The Affiliated Changzhou Tumor Hospital of Soochow University, Changzhou, China Cip
s Medical Center, Manila, the Philippines Siriraj Hospital, Mahidol University, Bangkok, Thailand National Cancer Hospital, Hanoi, Vietnam Ho Chi Minh City Oncology Hospital, Vietnam, Vietnam
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Squamous cell carcinoma of the uterine cervix 2. Stage IIB (>=4 cm in diameter) and IIIB disease (FIGO 2008) 3. Age; 20-70 years 4. PS; WHO 0-2 5. No prior chemotherapy, radiotherapy, and surgery to the pelvis 6. Life expectancy; longer than 6 months 7. Adequate bone marrow, hepatic, and renal functions; WBC>=3000/mm3 Hb>=10 g/dl Platelet>=100,000/mm3 Total bilirubin<=1.5 mg/dl (<=25.65 umol/L) AST/ALT<=2 times upper limit of normal Serum creatinine<=1.5 mg/dl (<=132.6 umol/L) 8. Written informed consent 9. Diagnostic images (CT of the abdomen and pelvis is needed, MRI of the pelvis is recommended but not mandatory) before starting EBRT. 10. No PALN metastasis on CT. (> 1 cm in minimum diameter)
Exclusion criteria
Exclusion criteria: 1. Severe concomitant illness 2. History of other malignancies within the past 5 years except basal cell carcinoma or squamous cell carcinoma in-situ of the skin 3. Tumor with infiltration of lower 1/3 of the vagina 4. Patients who are pregnant or lactating
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year overall survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year local control rate, acute and late toxicities | — |
Countries
Japan,Asia(except Japan)
Contacts
Public ContactNoriyuki Okonogi
National Institutes for Quantum and Radiological Sciences and Technology QST Hospital
Outcome results
None listed